Valneva SE (NASDAQ:VALN) Short Interest Up 111.0% in November

Valneva SE (NASDAQ:VALN) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 30,600 shares, an increase of 111.0% from the November 15th total of 14,500 shares. Based on an average trading volume of 23,500 shares, the short-interest ratio is presently 1.3 days. Approximately 0.0% of the shares of the stock are short sold.

Valneva Price Performance

VALN stock opened at $3.96 on Thursday. Valneva has a 1 year low of $3.82 and a 1 year high of $10.93. The firm has a market cap of $321.74 million, a P/E ratio of -30.46 and a beta of 1.99. The stock’s 50 day moving average price is $5.11 and its 200 day moving average price is $6.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its position in Valneva SE (NASDAQ:VALN) by 42.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,252 shares of the company’s stock after purchasing an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned approximately 0.13% of Valneva worth $649,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.